RebrandingJun 30, 2026, 07:31 AM
Plus Therapeutics to become Cerenome, trade as CNSY on Aug 3
AI Summary
Plus Therapeutics announced a comprehensive business update, including a rebrand to Cerenome and a change of its Nasdaq ticker to CNSY, effective August 3, 2026. The company affirmed its 2026 milestones guidance, highlighting significant commercial progress for its CNSide® Diagnostics platform, which now covers approximately 126 million lives. Additionally, Plus Therapeutics provided updates on its REYOBIQ™ clinical and manufacturing advancements, and its new AI strategy.
Key Highlights
- Company name changing from Plus Therapeutics to Cerenome.
- Nasdaq ticker changing from PSTV to CNSY, effective August 3, 2026.
- Affirmed anticipated 2026 milestones guidance.
- CNSide commercial coverage expanded to approximately 126 million people.
- CNSide performed 232 tests year-to-date, with 72 in June.
- REYOBIQ ReSPECT-GBM trial enrolled 31 of 34 target subjects.
- REYOBIQ ReSPECT-PBC trial first dosing expected in Q3 2026.
- New corporate website cerenome.com to launch with ticker change.
Price Impact
More from PSTV